Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O

Sensitive	O
and	O
receptor-mediated	O
regulation	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
.	O

We	O
show	O
that	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
[	O
OH	O
]	O
2D3	O
)	O
,	O
the	O
most	O
hormonally	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
modulates	O
sensitively	O
and	O
specifically	O
both	O
the	O
protein	O
and	O
messenger	B-RNA
RNA	I-RNA
accumulation	O
of	O
the	O
multilineage	B-protein
growth	I-protein
factor	I-protein
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
.	O

The	O
regulation	O
of	O
GM-CSF	B-protein
expression	O
is	O
seen	O
in	O
both	O
normal	B-cell_type
human	I-cell_type
mitogen-activated	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
T	B-cell_line
lymphocytes	I-cell_line
from	I-cell_line
a	I-cell_line
line	I-cell_line
(	I-cell_line
S-LB1	I-cell_line
)	I-cell_line
transformed	I-cell_line
with	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lymphotropic	I-cell_line
virus	I-cell_line
1	I-cell_line
(	O
HTLV-1	O
)	O
.	O

In	O
contrast	O
,	O
cells	O
from	O
a	O
HTLV-1	B-cell_line
transformed	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
line	I-cell_line
(	O
Ab-VDR	B-cell_line
)	O
established	O
from	O
a	O
patient	O
with	O
vitamin	O
D-resistant	O
rickets	O
type	O
II	O
with	O
undetectable	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
cellular	I-protein
receptors	I-protein
are	O
resistant	O
to	O
the	O
action	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Inhibition	O
of	O
GM-CSF	B-protein
expression	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
occur	O
independently	O
of	O
interleukin	B-protein
2	I-protein
regulation	O
and	O
is	O
probably	O
mediated	O
through	O
cellular	B-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
.	O

We	O
conclude	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
may	O
be	O
important	O
in	O
the	O
physiology	O
of	O
hematopoiesis	O
.	O

Granulocyte-Macrophage	NULL
Colony-stimulating	NULL
Factor	NULL
Sensitive	NULL
and	NULL
Receptor-mediated	NULL
Regulation	NULL
by	NULL
1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
in	NULL
Normal	NULL
Human	NULL
Peripheral	NULL
Blood	NULL
Lymphocytes	NULL
A.	NULL
Tobler	NULL
,	NULL
J.	NULL
Gasson	NULL
,	NULL
H.	NULL
Reichel	NULL
,	NULL
*	NULL
A.	NULL
W.	NULL
Norman	NULL
,	NULL
*	NULL
and	NULL
H.	NULL
P.	NULL
Koeffler	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Division	NULL
of	NULL
Hematology/Oncology	NULL
,	NULL
University	NULL
of	NULL
California	NULL
Los	NULL
Angeles	NULL
Medical	NULL
Center	NULL
,	NULL
Los	NULL
Angeles	NULL
,	NULL
California	NULL
90024	NULL
;	NULL
and	NULL
*Department	NULL
of	NULL
Biochemistry	NULL
,	NULL
University	NULL
of	NULL
California	NULL
,	NULL
Riverside	NULL
,	NULL
California	NULL
92521	NULL
Abstract	NULL
We	NULL
show	NULL
that	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
(	NULL
1,25	NULL
[	NULL
OH	NULL
}	NULL
;	NULL
D	NULL
;	NULL
)	NULL
,	NULL
the	NULL
most	NULL
hormonally	NULL
active	NULL
metabolite	NULL
of	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
modulates	NULL
sensitively	NULL
and	NULL
specifically	NULL
both	NULL
the	NULL
protein	NULL
and	NULL
messenger	NULL
RNA	NULL
accumulation	NULL
of	NULL
the	NULL
multilineage	NULL
growth	NULL
factor	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
GM-CSF	NULL
expression	NULL
is	NULL
seen	NULL
in	NULL
both	NULL
normal	NULL
human	NULL
mitogen-activated	NULL
T	NULL
lymphocytes	NULL
and	NULL
T	NULL
lymphocytes	NULL
from	NULL
a	NULL
line	NULL
(	NULL
S-LB1	NULL
)	NULL
transformed	NULL
with	NULL
human	NULL
T	NULL
cell	NULL
lymphotropic	NULL
virus	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
cells	NULL
from	NULL
a	NULL
HTLV-1	NULL
transformed	NULL
T	NULL
lymphocyte	NULL
line	NULL
(	NULL
Ab-VDR	NULL
)	NULL
established	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
vitamin	NULL
D-resistant	NULL
rickets	NULL
type	NULL
II	NULL
with	NULL
undetectable	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
cellular	NULL
receptors	NULL
are	NULL
resistant	NULL
to	NULL
the	NULL
action	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

Inhibition	NULL
of	NULL
GM-CSF	NULL
expression	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
can	NULL
occur	NULL
independently	NULL
of	NULL
interleukin	NULL
2	NULL
regulation	NULL
and	NULL
is	NULL
probably	NULL
mediated	NULL
through	NULL
cellular	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptors	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
may	NULL
be	NULL
important	NULL
in	NULL
the	NULL
physiology	NULL
of	NULL
hematopoiesis	NULL
.	NULL

Introduction	NULL
Evidence	NULL
is	NULL
accumulating	NULL
that	NULL
the	NULL
hormonally	NULL
active	NULL
metabolite	NULL
of	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
(	NULL
1,25	NULL
[	NULL
OH	NULL
]	NULL
;	NULL
D	NULL
;	NULL
)	NULL
,	NULL
'	NULL
might	NULL
play	NULL
an	NULL
important	NULL
role	NULL
as	NULL
an	NULL
immunohematopoietic	NULL
regulatory	NULL
hormone	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Specific	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptors	NULL
are	NULL
present	NULL
in	NULL
normal	NULL
human	NULL
mitogen-activated	NULL
and	NULL
malignant	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
and	NULL
myeloid	NULL
cells	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
enhances	NULL
the	NULL
in	NULL
vitro	NULL
differentiation	NULL
of	NULL
normal	NULL
and	NULL
leukemic	NULL
myeloid	NULL
stem	NULL
cells	NULL
towards	NULL
macrophages	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
inhibits	NULL
proliferation	NULL
and	NULL
suppresses	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
synthesis	NULL
of	NULL
mitogen-activated	NULL
T	NULL
lymphocytes	NULL
(	NULL
8-11	NULL
)	NULL
.	NULL

Hunian	NULL
macrophages	NULL
activated	NULL
by	NULL
y-interferon	NULL
synthesize	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
A.	NULL
Tobler	NULL
,	NULL
UCLA	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Division	NULL
of	NULL
Hematology/Oncology	NULL
,	NULL
11-240	NULL
Factor	NULL
Building	NULL
,	NULL
Los	NULL
Angeles	NULL
,	NULL
CA	NULL
90024	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
29	NULL
July	NULL
1986	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
23	NULL
December	NULL
1986	NULL
.	NULL

1	NULL
.	NULL

Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
1,2	NULL
5-dihydroxyvitamin	NULL
D	NULL
;	NULL
;	NULL
CM	NULL
,	NULL
conditioned	NULL
medium	NULL
;	NULL
EDs	NULL
,	NULL
dose	NULL
effective	NULL
in	NULL
achieving	NULL
half-maximal	NULL
response	NULL
;	NULL
GM-CFC	NULL
,	NULL
granulocyte-macrophage	NULL
colony-forming	NULL
cells	NULL
;	NULL
GM-CSF	NULL
,	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
;	NULL
HTLV-1	NULL
,	NULL
human	NULL
T	NULL
cell	NULL
lymphotropic	NULL
virus	NULL
1	NULL
;	NULL
IL-2	NULL
;	NULL
interleukin	NULL
2	NULL
;	NULL
PBL	NULL
,	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
;	NULL
PHA	NULL
,	NULL
phytohemagglutinin	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

©	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Clinical	NULL
Investigation	NULL
,	NULL
Inc.	NULL
700/06	NULL
$	NULL
1.00	NULL
Volume	NULL
79	NULL
,	NULL
June	NULL
1987	NULL
,	NULL
1700-1705	NULL
1700	NULL
Survival	NULL
,	NULL
proliferation	NULL
,	NULL
and	NULL
differentiation	NULL
of	NULL
hematopoietic	NULL
cells	NULL
are	NULL
dependent	NULL
on	NULL
colony-stimulating	NULL
factors	NULL
(	NULL
CSF	NULL
)	NULL
.	NULL

The	NULL
granulocyte-macrophage	NULL
CSF	NULL
(	NULL
GM-CSF	NULL
)	NULL
,	NULL
which	NULL
is	NULL
synthesized	NULL
by	NULL
activated	NULL
T	NULL
lymphocytes	NULL
,	NULL
has	NULL
been	NULL
cloned	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

Recombinant	NULL
and	NULL
natural	NULL
GM-CSF	NULL
possess	NULL
multilineage	NULL
colony-stimulating	NULL
activity	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
and	NULL
also	NULL
enhances	NULL
mature	NULL
cell	NULL
function	NULL
of	NULL
neutrophils	NULL
and	NULL
eosinophils	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

We	NULL
report	NULL
here	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
sensitively	NULL
and	NULL
specifically	NULL
inhibits	NULL
the	NULL
expression	NULL
of	NULL
GM-CSF	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Methods	NULL
Compounds	NULL
.	NULL

The	NULL
vitamin	NULL
D	NULL
,	NULL
metabolites	NULL
(	NULL
1,25	NULL
[	NULL
OH	NULL
]	NULL
;	NULL
D	NULL
;	NULL
,	NULL
1,24,25-	NULL
[	NULL
OH	NULL
]	NULL
;	NULL
D	NULL
;	NULL
,	NULL
and	NULL
25	NULL
[	NULL
OH	NULL
]	NULL
JD	NULL
;	NULL
)	NULL
were	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr.	NULL
M.	NULL
Uskokovic	NULL
,	NULL
Hoffmann-La	NULL
Roche	NULL
,	NULL
Inc.	NULL
,	NULL
Nutley	NULL
,	NULL
NJ	NULL
.	NULL

The	NULL
compounds	NULL
were	NULL
dissolved	NULL
in	NULL
100	NULL
%	NULL
ethanol	NULL
to	NULL
a	NULL
stock	NULL
concentration	NULL
of	NULL
1	NULL
X	NULL
107	NULL
M	NULL
and	NULL
stored	NULL
at	NULL
-20°C	NULL
.	NULL

The	NULL
various	NULL
concentrations	NULL
(	NULL
10~	NULL
``	NULL
-10~	NULL
'	NULL
M	NULL
)	NULL
were	NULL
obtained	NULL
by	NULL
diluting	NULL
the	NULL
stock	NULL
solutions	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
ethanol	NULL
did	NULL
not	NULL
exceed	NULL
0.1	NULL
%	NULL
.	NULL

Recombinant	NULL
human	NULL
IL-2	NULL
was	NULL
generously	NULL
provided	NULL
by	NULL
Jiirgen	NULL
Besemer	NULL
(	NULL
Sandoz	NULL
Ltd.	NULL
,	NULL
Vienna	NULL
,	NULL
Aus-tria	NULL
)	NULL
.	NULL

Phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
(	NULL
Wellcome	NULL
Diagnostics	NULL
,	NULL
Datford	NULL
,	NULL
England	NULL
)	NULL
was	NULL
used	NULL
in	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.5	NULL
%	NULL
.	NULL

Cells	NULL
and	NULL
liquid	NULL
culture	NULL
assay	NULL
.	NULL

The	NULL
human	NULL
cell	NULL
lines	NULL
S-LB1	NULL
(	NULL
20	NULL
)	NULL
,	NULL
Ab-VDR	NULL
(	NULL
H.	NULL
P.	NULL
Koeffier	NULL
and	NULL
A.	NULL
W.	NULL
Norman	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
,	NULL
HL-60	NULL
(	NULL
21	NULL
)	NULL
,	NULL
and	NULL
KG-1	NULL
(	NULL
22	NULL
)	NULL
were	NULL
maintained	NULL
in	NULL
suspension	NULL
culture	NULL
T	NULL
flask	NULL
(	NULL
Miles	NULL
Laboratories	NULL
Inc.	NULL
,	NULL
Naperville	NULL
,	NULL
IL	NULL
)	NULL
,	NULL
containing	NULL
alpha	NULL
medium	NULL
(	NULL
Flow	NULL
Laboratories	NULL
,	NULL
Inc.	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
(	NULL
Irvine	NULL
Scientific	NULL
,	NULL
Santa	NULL
Ana	NULL
,	NULL
CA	NULL
)	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
of	NULL
7	NULL
%	NULL
CO	NULL
;	NULL
.	NULL

The	NULL
medium	NULL
was	NULL
changed	NULL
two	NULL
times	NULL
a	NULL
week	NULL
.	NULL

Human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
PBL	NULL
)	NULL
and	NULL
human	NULL
bone	NULL
marrow	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
normal	NULL
volunteers	NULL
and	NULL
isolated	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
(	NULL
1.077	NULL
g/m	NULL
!	NULL
)	NULL

(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Monocytes	NULL
were	NULL
removed	NULL
from	NULL
PBL	NULL
by	NULL
their	NULL
ability	NULL
to	NULL
adhere	NULL
to	NULL
plastic	NULL
for	NULL
6	NULL
h.	NULL
The	NULL
PBL	NULL
and	NULL
the	NULL
human	NULL
HTLV-i	NULL
immortalized	NULL
T	NULL
lymphocyte	NULL
cell	NULL
lines	NULL
(	NULL
S-LB1	NULL
,	NULL
Ab-VDR	NULL
)	NULL
were	NULL
cultured	NULL
for	NULL
2	NULL
d	NULL
at	NULL
1	NULL
X	NULL
10°	NULL
cells/ml	NULL
in	NULL
alpha	NULL
medium-supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
various	NULL
additives	NULL
(	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
compounds	NULL
,	NULL
PHA	NULL
,	NULL
IL-2	NULL
)	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
of	NULL
7	NULL
%	NULL
CO	NULL
;	NULL
.	NULL

The	NULL
conditioned	NULL
media	NULL
(	NULL
CM	NULL
)	NULL
were	NULL
stored	NULL
at	NULL
4°C	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
not	NULL
affected	NULL
in	NULL
the	NULL
various	NULL
experimental	NULL
protocols	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

Colony	NULL
formation	NULL
assay	NULL
by	NULL
two-layer	NULL
agar	NULL
techniques	NULL
.	NULL

The	NULL
underlayer	NULL
was	NULL
plated	NULL
in	NULL
1-ml	NULL
portions	NULL
in	NULL
35-mm	NULL
petri	NULL
dishes	NULL
(	NULL
Miles	NULL
Laboratories	NULL
Inc.	NULL
)	NULL
containing	NULL
0.5	NULL
%	NULL
agar	NULL
,	NULL
alpha	NULL
medium	NULL
,	NULL
16	NULL
%	NULL
FCS	NULL
and	NULL
CM	NULL
from	NULL
PBL	NULL
as	NULL
a	NULL
source	NULL
of	NULL
CSF	NULL
.	NULL

CM	NULL
obtained	NULL
from	NULL
the	NULL
human	NULL
T	NULL
lymphocyte	NULL
Mo	NULL
cell	NULL
line	NULL
was	NULL
used	NULL
for	NULL
control	NULL
purpose	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1.5	NULL
%	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
overlayer	NULL
contained	NULL
the	NULL
GM-CSF	NULL
responder	NULL
cells	NULL
(	NULL
bone	NULL
marrow	NULL
,	NULL
KG-1	NULL
)	NULL
,	NULL
alpha	NULL
medium	NULL
,	NULL
16	NULL
%	NULL
FCS	NULL
,	NULL
penicillin	NULL
,	NULL
streptomycin	NULL
,	NULL
and	NULL
0.3	NULL
%	NULL
agar	NULL
.	NULL

The	NULL
culture	NULL
dishes	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
with	NULL
7	NULL
%	NULL
CO	NULL
;	NULL
for	NULL
10-13	NULL
d.	NULL
Colonies	NULL
(	NULL
>	NULL
40	NULL
cells	NULL
)	NULL
were	NULL
counted	NULL
using	NULL
an	NULL
inverted	NULL
microscope	NULL
.	NULL

Complementary	NULL
DNA	NULL
(	NULL
cDNA	NULL
)	NULL
probes	NULL
,	NULL
Northern	NULL
blot	NULL
technique	NULL
.	NULL

The	NULL
IL-2	NULL
cDNA	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
S.	NULL
Clarke	NULL
,	NULL
Genetics	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
(	NULL
24	NULL
)	NULL
.	NULL

The	NULL
IL-2	NULL
receptor	NULL
cDNA	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
T.	NULL
Nikaido	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
IL-2	NULL
and	NULL
the	NULL
IL-2	NULL
receptor	NULL
probes	NULL
were	NULL
[	NULL
**P	NULL
]	NULL
-labeled	NULL
by	NULL
the	NULL
A.	NULL
Tobler	NULL
,	NULL
J.	NULL
Gasson	NULL
,	NULL
H.	NULL
Reichel	NULL
,	NULL
A.	NULL
W.	NULL
Norman	NULL
,	NULL
and	NULL
H.	NULL
P.	NULL
Koeffler	NULL
random	NULL
priming	NULL
method	NULL
as	NULL
described	NULL
(	NULL
26	NULL
)	NULL
.	NULL

The	NULL
GM-CSF	NULL
probes	NULL
were	NULL
[	NULL
*P	NULL
]	NULL
-labeled	NULL
by	NULL
nick	NULL
translation	NULL
(	NULL
27	NULL
)	NULL
.	NULL

For	NULL
cytoplasmic	NULL
RNA	NULL
,	NULL
freshly	NULL
harvested	NULL
cells	NULL
were	NULL
suspended	NULL
in	NULL
hy-potonic	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
[	NULL
pH	NULL
7.4	NULL
]	NULL
,	NULL
1	NULL
mM	NULL
KCI	NULL
,	NULL
3	NULL
mM	NULL
MgCl	NULL
;	NULL
)	NULL
and	NULL
were	NULL
lysed	NULL
with	NULL
Nonidet	NULL
P-40	NULL
(	NULL
0.3	NULL
%	NULL
)	NULL
.	NULL

Nuclei	NULL
were	NULL
removed	NULL
by	NULL
cen-trifugation	NULL
.	NULL

Cytoplasmic	NULL
RNA	NULL
was	NULL
extracted	NULL
by	NULL
the	NULL
phenol/chlorofom	NULL
method	NULL
as	NULL
essentially	NULL
described	NULL
(	NULL
28	NULL
)	NULL
and	NULL
quantified	NULL
by	NULL
absorbance	NULL
at	NULL
260	NULL
nm	NULL
.	NULL

Samples	NULL
were	NULL
denatured	NULL
at	NULL
65°C	NULL
for	NULL
10	NULL
min	NULL
,	NULL
size-separated	NULL
by	NULL
an	NULL
agarose	NULL
formaldehyde	NULL
gel	NULL
(	NULL
1	NULL
%	NULL
agarose	NULL
[	NULL
Bethesda	NULL
Research	NULL
Laboratories	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
]	NULL
,	NULL
50	NULL
mM	NULL
Na	NULL
acetate	NULL
,	NULL
10	NULL
mM	NULL
Na	NULL
;	NULL
EDTA	NULL
,	NULL
200	NULL
mM	NULL
MOPS	NULL
,	NULL
and	NULL
2.2	NULL
M	NULL
formaldehyde	NULL
)	NULL
,	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
nylon	NULL
membrane	NULL
filter	NULL
(	NULL
ICN	NULL
Biomedicals	NULL
Inc.	NULL
,	NULL
Irvine	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Filters	NULL
were	NULL
dried	NULL
,	NULL
baked	NULL
at	NULL
80°C	NULL
in	NULL
vacuo	NULL
for	NULL
2	NULL
h	NULL
,	NULL
and	NULL
then	NULL
prehybridized	NULL
for	NULL
16-24	NULL
h.	NULL
Hybrid-izations	NULL
with	NULL
[	NULL
**P	NULL
]	NULL
-labeled	NULL
cDNA	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
cpm/ml	NULL
!	NULL
)	NULL

were	NULL
performed	NULL
at	NULL
42°C	NULL
for	NULL
16-24	NULL
h	NULL
in	NULL
a	NULL
solution	NULL
containing	NULL
50	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
formamide	NULL
,	NULL
2	NULL
%	NULL
SSC	NULL
(	NULL
1	NULL
%	NULL
SSC	NULL
is	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
15	NULL
mM	NULL
sodium	NULL
citrate	NULL
)	NULL
,	NULL
5	NULL
%	NULL
Denhardts	NULL
(	NULL
1	NULL
%	NULL
Denhardts	NULL
is	NULL
0.02	NULL
%	NULL
Ficoll/0.02	NULL
%	NULL
polyvinylpyrrolidone/0.02	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
)	NULL
,	NULL
0.1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
10	NULL
%	NULL
{	NULL
vol/vol	NULL
)	NULL
dextran	NULL
sulfate	NULL
(	NULL
500,000	NULL
mol	NULL
wt	NULL
)	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
,	NULL
and	NULL
100	NULL
ug/ml	NULL
salmon	NULL
sperm	NULL
DNA	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

Filters	NULL
were	NULL
washed	NULL
to	NULL
a	NULL
stringency	NULL
of	NULL
0.1	NULL
%	NULL
SSC	NULL
,	NULL
1	NULL
%	NULL
SDS	NULL
at	NULL
65°C	NULL
and	NULL
exposed	NULL
for	NULL
24-48	NULL
h	NULL
at	NULL
-70°C	NULL
to	NULL
XAR-5	NULL
film	NULL
(	NULL
Eastman	NULL
Kodak	NULL
Co.	NULL
,	NULL
Rochester	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Measurement	NULL
of	NULL
incorporation	NULL
.	NULL

S-LBI	NULL
cells	NULL
(	NULL
1	NULL
%	NULL
10°/	NULL
ml	NULL
)	NULL
were	NULL
exposed	NULL
in	NULL
24-well	NULL
plates	NULL
(	NULL
Miles	NULL
Laboratories	NULL
Inc.	NULL
)	NULL
in	NULL
quadruplicates	NULL
for	NULL
various	NULL
durations	NULL
(	NULL
0	NULL
,	NULL
6	NULL
,	NULL
48	NULL
h	NULL
)	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
M	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
pulsed	NULL
with	NULL
0.5	NULL
of	NULL
[	NULL
``	NULL
*Cjuridine	NULL
(	NULL
New	NULL
England	NULL
Nuclear	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
for	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
,	NULL
washed	NULL
twice	NULL
in	NULL
PBS	NULL
,	NULL
precipitated	NULL
in	NULL
5	NULL
%	NULL
trichlo-roacetic	NULL
acid	NULL
(	NULL
TCA	NULL
)	NULL
for	NULL
10	NULL
min	NULL
,	NULL
washed	NULL
twice	NULL
in	NULL
5	NULL
%	NULL
TCA	NULL
,	NULL
and	NULL
heated	NULL
at	NULL
80°C	NULL
for	NULL
60	NULL
min	NULL
.	NULL

200	NULL
u	NULL
]	NULL
of	NULL
each	NULL
sample	NULL
was	NULL
counted	NULL
by	NULL
liquid	NULL
scintillation	NULL
.	NULL

Measurement	NULL
of	NULL
[	NULL
'	NULL
H	NULL
|thymidine	NULL
incorporation	NULL
.	NULL

PBL	NULL
(	NULL
1	NULL
X	NULL
10°/ml	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0.5	NULL
%	NULL
PHA	NULL
and	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
10~	NULL
'	NULL
M	NULL
)	NULL
in	NULL
equal	NULL
volumes	NULL
(	NULL
100	NULL
1	NULL
)	NULL
in	NULL
triplicates	NULL
in	NULL
96-well	NULL
plates	NULL
(	NULL
Corning	NULL
Glass	NULL
Works	NULL
,	NULL
Corning	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

After	NULL
48	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
pulsed	NULL
with	NULL
1	NULL
LCi	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
(	NULL
ICN	NULL
Biomedicals	NULL
Inc.	NULL
)	NULL
for	NULL
5	NULL
h	NULL
at	NULL
37°C	NULL
and	NULL
harvested	NULL
into	NULL
glass	NULL
filter	NULL
fiber	NULL
with	NULL
a	NULL
Mash	NULL
II	NULL
cell	NULL
harvester	NULL
(	NULL
Skatron	NULL
,	NULL
Inc.	NULL
,	NULL
Sterling	NULL
,	NULL
VA	NULL
)	NULL
and	NULL
counted	NULL
by	NULL
liquid	NULL
scintillation	NULL
.	NULL

Results	NULL
Modulation	NULL
of	NULL
GM-CSF	NULL
protein	NULL
levels	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
influence	NULL
of	NULL
IL-2	NULL
on	NULL
GM-CSF	NULL
expression	NULL
in	NULL
peripheral	NULL
blood	NULL
lym-phocytes	NULL
:	NULL
dose	NULL
response	NULL
.	NULL

The	NULL
PBL	NULL
(	NULL
1	NULL
X	NULL
10°/ml	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
concentrations	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
107	NULL
``	NULL
'-10~	NULL
``	NULL
M	NULL
)	NULL
and	NULL
PHA	NULL
(	NULL
0.5	NULL
%	NULL
)	NULL
.	NULL

After	NULL
2	NULL
d	NULL
,	NULL
CSF	NULL
activity	NULL
of	NULL
the	NULL
CM	NULL
was	NULL
assayed	NULL
for	NULL
stimulation	NULL
of	NULL
clonal	NULL
growth	NULL
of	NULL
both	NULL
normal	NULL
human	NULL
granulocyte-macrophage	NULL
colony-forming	NULL
cells	NULL
(	NULL
GM-CFC	NULL
)	NULL
and	NULL
the	NULL
human	NULL
myeloblastic	NULL
leukemic	NULL
cell	NULL
line	NULL
KG-1	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
)	NULL
.	NULL

Clonal	NULL
growth	NULL
of	NULL
both	NULL
GM-CFC	NULL
and	NULL
KG-1	NULL
cells	NULL
is	NULL
dependent	NULL
on	NULL
CSF	NULL
(	NULL
22	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
decreased	NULL
levels	NULL
of	NULL
GM-CSF	NULL
protein	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
with	NULL
a	NULL
50	NULL
%	NULL
reduction	NULL
of	NULL
CSF	NULL
activity	NULL
(	NULL
EDs	NULL
,	NULL
)	NULL
at	NULL
~	NULL
5	NULL
X	NULL
10~'°	NULL
M	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
when	NULL
tested	NULL
on	NULL
clonal	NULL
growth	NULL
of	NULL
GM-CFC	NULL
and	NULL
KG-1	NULL
cells	NULL
.	NULL

Control	NULL
dishes	NULL
containing	NULL
no	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
formed	NULL
127+8	NULL
(	NULL
+SD	NULL
)	NULL
GM-CFC	NULL
and	NULL
62+10	NULL
(	NULL
+SD	NULL
)	NULL
KG-1	NULL
colonies	NULL
.	NULL

No	NULL
difference	NULL
in	NULL
colony	NULL
formation	NULL
could	NULL
be	NULL
observed	NULL
when	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
10~*	NULL
M	NULL
)	NULL
was	NULL
added	NULL
directly	NULL
to	NULL
the	NULL
culture	NULL
dishes	NULL
containing	NULL
CM	NULL
of	NULL
PHA-activated	NULL
PBL	NULL
compared	NULL
with	NULL
the	NULL
control	NULL
dishes	NULL
containing	NULL
CM	NULL
of	NULL
PHA-stimulated	NULL
PBL	NULL
only	NULL
.	NULL

Prior	NULL
studies	NULL
showed	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
decreased	NULL
proliferation	NULL
and	NULL
IL-2	NULL
synthesis	NULL
by	NULL
PBL	NULL
(	NULL
8-11	NULL
)	NULL
.	NULL

We	NULL
examined	NULL
,	NULL
therefore	NULL
,	NULL
whether	NULL
IL-2	NULL
might	NULL
affect	NULL
the	NULL
modulation	NULL
of	NULL
GM-CSF	NULL
production	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
lymphocytes	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
4	NULL
)	NULL
.	NULL

The	NULL
PBL	NULL
were	NULL
cultured	NULL
for	NULL
48	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
high	NULL
concentration	NULL
of	NULL
recombinant	NULL
human	NULL
IL-2	NULL
(	NULL
200	NULL
ng/ml/10©	NULL
cells	NULL
)	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
GM-CSF	NULL
Activity	NULL
(	NULL
%	NULL
Control	NULL
)	NULL
mRNA	NULL
reduction	NULL
(	NULL
%	NULL
)	NULL
80	NULL
0	NULL
13	NULL
77	NULL
90	NULL
84	NULL
#	NULL
s	NULL
-0.9	NULL
kb	NULL
40	NULL
o	NULL
c	NULL
goe	NULL
®	NULL
o	NULL
o	NULL
o	NULL
o	NULL
10°	NULL
``	NULL
10°	NULL
``	NULL
10	NULL
``	NULL
io	NULL
``	NULL
10	NULL
``	NULL
1,25	NULL
(	NULL
0H1	NULL
;	NULL
03	NULL
[	NULL
M	NULL
]	NULL
1.25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D3	NULL
(	NULL
M	NULL
)	NULL
C	NULL
-	NULL
3.5	NULL
kb	NULL
-1.4	NULL
kb	NULL
5	NULL
a	NULL
s	NULL
g	NULL
2	NULL
op	NULL
2	NULL
1.25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
M	NULL
)	NULL
D	NULL
100	NULL
E	NULL
80	NULL
3	NULL
mRNA	NULL
reduction	NULL
(	NULL
%	NULL
)	NULL
E.	NULL
60	NULL
0	NULL
84	NULL
73	NULL
45	NULL
&	NULL
ao	NULL
320	NULL
i	NULL
#	NULL
#	NULL
-o.9kb	NULL
Fa	NULL
0	NULL
0	NULL
an	NULL
24	NULL
1°	NULL
0	NULL
48	NULL
24	NULL
6	NULL
(	NULL
h	NULL
)	NULL
Figure	NULL
1	NULL
.	NULL

Modulation	NULL
of	NULL
GM-CSF	NULL
expression	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
PBL	NULL
.	NULL

Dose-response	NULL
studies	NULL
(	NULL
4-C	NULL
)	NULL
:	NULL
(	NULL
4	NULL
)	NULL
Regulation	NULL
of	NULL
GM-CSF	NULL
protein	NULL
production	NULL
.	NULL

PBL	NULL
were	NULL
cultured	NULL
for	NULL
48	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PHA	NULL
and	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

GM-CSF	NULL
activity	NULL
of	NULL
the	NULL
CM	NULL
was	NULL
tested	NULL
by	NULL
measuring	NULL
clonal	NULL
growth	NULL
of	NULL
both	NULL
a	NULL
normal	NULL
human	NULL
GM-CFC	NULL
(	NULL
0	NULL
)	NULL
and	NULL
a	NULL
leukemic	NULL
myeloblastic	NULL
cell	NULL
line	NULL
KG-1	NULL
(	NULL
@	NULL
)	NULL
.	NULL

In	NULL
a	NULL
parellel	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
recombinant	NULL
IL-2	NULL
(	NULL
200	NULL
ng/ml	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cultures	NULL
and	NULL
the	NULL
CM	NULL
was	NULL
assayed	NULL
on	NULL
GM-CFC	NULL
(	NULL
e	NULL
)	NULL
.	NULL

The	NULL
IL-2	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
clonal	NULL
growth	NULL
,	NULL
(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
Regulation	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
levels	NULL
(	NULL
Northern	NULL
blots	NULL
)	NULL
.	NULL

PBL	NULL
were	NULL
incubated	NULL
for	NULL
48	NULL
hours	NULL
with	NULL
PHA	NULL
and	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

When	NULL
probed	NULL
with	NULL
GM-CSF	NULL
cDNA	NULL
,	NULL
a	NULL
single	NULL
band	NULL
was	NULL
detected	NULL
at	NULL
0.9	NULL
kb	NULL
consistent	NULL
with	NULL
the	NULL
known	NULL
length	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
(	NULL
B	NULL
)	NULL
.	NULL

The	NULL
same	NULL
Northern	NULL
blot	NULL
was	NULL
reprobed	NULL
with	NULL
IL-2	NULL
receptor	NULL
cDNA	NULL
,	NULL
as	NULL
a	NULL
control	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Two	NULL
bands	NULL
were	NULL
observed	NULL
at	NULL
1.4	NULL
and	NULL
3.5	NULL
kb	NULL
consistent	NULL
with	NULL
IL-2	NULL
receptor	NULL
mRNA	NULL
.	NULL

Time-response	NULL
studies	NULL
(	NULL
D	NULL
and	NULL
£	NULL
)	NULL
:	NULL
(	NULL
D	NULL
)	NULL
Regulation	NULL
of	NULL
GM-CSF	NULL
protein	NULL
production	NULL
.	NULL

PBL	NULL
were	NULL
exposed	NULL
to	NULL
PHA	NULL
and	NULL
for	NULL
various	NULL
durations	NULL
(	NULL
12-48	NULL
h	NULL
)	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
1078	NULL
M	NULL
)	NULL
.	NULL

All	NULL
time	NULL
points	NULL
were	NULL
harvested	NULL
after	NULL
48	NULL
h.	NULL
GM-CSF	NULL
activity	NULL
was	NULL
assayed	NULL
on	NULL
GM-CFC	NULL
.	NULL

(	NULL
E	NULL
)	NULL
Regulation	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
levels	NULL
(	NULL
Northern	NULL
blot	NULL
)	NULL
.	NULL

PHA-activated	NULL
PBL	NULL
were	NULL
cultured	NULL
for	NULL
various	NULL
durations	NULL
(	NULL
6-48	NULL
h	NULL
)	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
10~	NULL
'	NULL
M	NULL
)	NULL
.	NULL

PBL	NULL
at	NULL
all	NULL
time	NULL
points	NULL
were	NULL
harvested	NULL
after	NULL
48	NULL
h.	NULL
Each	NULL
experiment	NULL
in	NULL
A	NULL
and	NULL
D	NULL
represents	NULL
the	NULL
mean+SD	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
with	NULL
PBL	NULL
from	NULL
three	NULL
different	NULL
donors	NULL
.	NULL

RNA	NULL
was	NULL
extracted	NULL
as	NULL
described	NULL
in	NULL
Methods	NULL
.	NULL

Each	NULL
lane	NULL
in	NULL
B	NULL
,	NULL
C	NULL
,	NULL
and	NULL
E	NULL
contains	NULL
30	NULL
ug	NULL
cytoplasmic	NULL
RNA	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
a	NULL
percent	NULL
reduction	NULL
of	NULL
mRNA	NULL
accumulation	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
untreated	NULL
control	NULL
sample	NULL
not	NULL
exposed	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
determined	NULL
by	NULL
densitometry	NULL
on	NULL
different	NULL
exposures	NULL
of	NULL
preflashed	NULL
autoradiograms	NULL
)	NULL
.	NULL

(	NULL
10-	NULL
``	NULL
'-10~	NULL
``	NULL
M	NULL
)	NULL
and	NULL
PHA	NULL
(	NULL
0.5	NULL
%	NULL
)	NULL
;	NULL
the	NULL
CM	NULL
was	NULL
assayed	NULL
for	NULL
stimulation	NULL
of	NULL
GM-CFC	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
addition	NULL
of	NULL
IL-2	NULL
to	NULL
the	NULL
cultures	NULL
slightly	NULL
blunted	NULL
but	NULL
did	NULL
not	NULL
reverse	NULL
the	NULL
inhibitory	NULL
action	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
GM-CSF	NULL
protein	NULL
activity	NULL
.	NULL

The	NULL
IL-2	NULL
alone	NULL
Colony-stimulating	NULL
Factor	NULL
Regulation	NULL
by	NULL
1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
1701	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
clonal	NULL
growth	NULL
of	NULL
GM-CFC	NULL
.	NULL

CM	NULL
from	NULL
control	NULL
cultures	NULL
(	NULL
PHA	NULL
0.5	NULL
%	NULL
,	NULL
no	NULL
IL-2	NULL
,	NULL
no	NULL
1,25	NULL
[	NULL
OH	NULL
]	NULL
;	NULL
D	NULL
;	NULL
)	NULL
stimulated	NULL
a	NULL
mean	NULL
243+8	NULL
(	NULL
+SD	NULL
)	NULL
GM-CFC	NULL
per	NULL
2	NULL
X	NULL
10°	NULL
mononuclear	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

Modulation	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
levels	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
PBL	NULL
:	NULL
dose	NULL
response	NULL
.	NULL

The	NULL
modulation	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
levels	NULL
of	NULL
PBL	NULL
cultured	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
determined	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
.	NULL

The	NULL
PBL	NULL
were	NULL
pooled	NULL
from	NULL
seven	NULL
different	NULL
donors	NULL
,	NULL
exposed	NULL
for	NULL
2	NULL
d	NULL
to	NULL
increasing	NULL
concentrations	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
10~	NULL
``	NULL
-10~®	NULL
M	NULL
)	NULL
and	NULL
PHA	NULL
(	NULL
0.5	NULL
%	NULL
)	NULL
and	NULL
the	NULL
mRNA	NULL
was	NULL
extracted	NULL
.	NULL

A	NULL
single	NULL
band	NULL
of	NULL
hybridization	NULL
was	NULL
detected	NULL
at	NULL
0.9	NULL
kb	NULL
,	NULL
which	NULL
is	NULL
consistent	NULL
with	NULL
GM-CSF	NULL
mRNA	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

The	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
reduced	NULL
mRNA	NULL
accumulation	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
with	NULL
an	NULL
EDs	NULL
,	NULL
of	NULL
~	NULL
5	NULL
X	NULL
107	NULL
``	NULL
M	NULL
as	NULL
determined	NULL
by	NULL
densitometry	NULL
reading	NULL
.	NULL

The	NULL
same	NULL
Northern	NULL
blot	NULL
was	NULL
washed	NULL
and	NULL
reprobed	NULL
with	NULL
a	NULL
human	NULL
cDNA	NULL
for	NULL
the	NULL
IL-2	NULL
receptor	NULL
gene	NULL
to	NULL
exclude	NULL
a	NULL
nonspecific	NULL
degradation	NULL
of	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
C	NULL
)	NULL
.	NULL

Two	NULL
classes	NULL
of	NULL
IL-2	NULL
receptor	NULL
mRNA	NULL
could	NULL
be	NULL
observed	NULL
at	NULL
1.4	NULL
and	NULL
3.5	NULL
kb	NULL
,	NULL
which	NULL
is	NULL
in	NULL
accordance	NULL
with	NULL
previously	NULL
reported	NULL
data	NULL
(	NULL
25	NULL
)	NULL
.	NULL

No	NULL
significant	NULL
change	NULL
of	NULL
IL-2	NULL
receptor	NULL
mRNA	NULL
(	NULL
1.4-kb	NULL
band	NULL
)	NULL
could	NULL
be	NULL
detected	NULL
.	NULL

Modulation	NULL
of	NULL
GM-CSF	NULL
protein	NULL
and	NULL
mRNA	NULL
levels	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
PBL	NULL
:	NULL
time	NULL
response	NULL
.	NULL

We	NULL
examined	NULL
whether	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
might	NULL
be	NULL
able	NULL
to	NULL
down-regulate	NULL
protein	NULL
and	NULL
mRNA	NULL
levels	NULL
of	NULL
GM-CSF	NULL
in	NULL
PBL	NULL
already	NULL
activated	NULL
by	NULL
PHA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
D	NULL
and	NULL
E	NULL
)	NULL
.	NULL

For	NULL
all	NULL
time	NULL
points	NULL
,	NULL
the	NULL
PBL	NULL
were	NULL
exposed	NULL
for	NULL
48	NULL
h	NULL
to	NULL
PHA	NULL
(	NULL
0.5	NULL
%	NULL
)	NULL
.	NULL

The	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
107°	NULL
M	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cultures	NULL
at	NULL
times	NULL
0	NULL
,	NULL
24	NULL
,	NULL
36	NULL
h	NULL
for	NULL
the	NULL
protein	NULL
studies	NULL
,	NULL
and	NULL
0	NULL
,	NULL
24	NULL
,	NULL
42	NULL
h	NULL
for	NULL
the	NULL
mRNA	NULL
studies	NULL
.	NULL

Control	NULL
samples	NULL
were	NULL
stimulated	NULL
by	NULL
PHA	NULL
alone	NULL
.	NULL

We	NULL
found	NULL
that	NULL
a	NULL
12-h	NULL
exposure	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
inhibited	NULL
GM-CSF	NULL
protein	NULL
production	NULL
by	NULL
~	NULL
50	NULL
%	NULL
in	NULL
PBL	NULL
previously	NULL
activated	NULL
with	NULL
PHA	NULL
for	NULL
36	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
D	NULL
)	NULL
;	NULL
and	NULL
a	NULL
6-h	NULL
exposure	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
sufficient	NULL
to	NULL
reduce	NULL
mRNA	NULL
levels	NULL
of	NULL
GM-CSF	NULL
by	NULL
~	NULL
50	NULL
%	NULL
in	NULL
PBL	NULL
previously	NULL
activated	NULL
for	NULL
42	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
E	NULL
)	NULL
.	NULL

___	NULL
Regulation	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
levels	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
a	NULL
HTLV-1	NULL
immortalized	NULL
T	NULL
lymphocyte	NULL
line	NULL
(	NULL
S-LB1	NULL
)	NULL
.	NULL

We	NULL
performed	NULL
a	NULL
parallel	NULL
series	NULL
of	NULL
experiments	NULL
using	NULL
a	NULL
human	NULL
T	NULL
lymphocyte	NULL
line	NULL
(	NULL
S-LB1	NULL
)	NULL
established	NULL
by	NULL
infection	NULL
of	NULL
normal	NULL
human	NULL
T	NULL
lymphocytes	NULL
with	NULL
HTLV-1	NULL
(	NULL
20	NULL
)	NULL
.	NULL

These	NULL
cells	NULL
constitutively	NULL
synthesize	NULL
GM-CSF	NULL
and	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
IL-2	NULL
receptors	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

S-LBI	NULL
cells	NULL
were	NULL
exposed	NULL
for	NULL
48	NULL
h	NULL
to	NULL
increasing	NULL
concentrations	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
10~	NULL
``	NULL
-10~	NULL
'	NULL
M	NULL
)	NULL
(	NULL
Figs	NULL
.	NULL

2	NULL
4	NULL
)	NULL
.	NULL

The	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
decreased	NULL
GM-CSF	NULL
mRNA	NULL
levels	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
as	NULL
shown	NULL
on	NULL
the	NULL
Northern	NULL
blot	NULL
,	NULL
and	NULL
a	NULL
50	NULL
%	NULL
reduction	NULL
of	NULL
mRNA	NULL
occurred	NULL
at	NULL
~	NULL
2.5	NULL
X	NULL
10~	NULL
``	NULL
M.	NULL
Time-response	NULL
experiments	NULL
showed	NULL
that	NULL
a	NULL
50	NULL
%	NULL
decrease	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
accumulation	NULL
occurred	NULL
within	NULL
6	NULL
h	NULL
of	NULL
exposure	NULL
of	NULL
S-LB1	NULL
cells	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
,	NULL
;	NULL
(	NULL
107°	NULL
M	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
)	NULL
.	NULL

For	NULL
control	NULL
purpose	NULL
,	NULL
the	NULL
same	NULL
samples	NULL
were	NULL
reprobed	NULL
with	NULL
IL-2	NULL
receptor	NULL
cDNA	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
C	NULL
)	NULL
.	NULL

Only	NULL
a	NULL
slight	NULL
change	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
mRNA	NULL
levels	NULL
(	NULL
1.4-kb	NULL
band	NULL
)	NULL
could	NULL
be	NULL
detected	NULL
when	NULL
S-LBI1	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
107°	NULL
M	NULL
)	NULL
,	NULL
as	NULL
compared	NULL
to	NULL
the	NULL
marked	NULL
decrease	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
levels	NULL
.	NULL

Receptor-mediated	NULL
modulation	NULL
of	NULL
GM-CSF	NULL
expression	NULL
by	NULL
vitamin	NULL
D	NULL
;	NULL
seco-steroids	NULL
.	NULL

We	NULL
first	NULL
studied	NULL
the	NULL
ability	NULL
of	NULL
other	NULL
metabolites	NULL
of	NULL
vitamin	NULL
D	NULL
;	NULL
to	NULL
regulate	NULL
the	NULL
accumulation	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
by	NULL
S-LB1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
4	NULL
)	NULL
.	NULL

The	NULL
S-LBI1	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
48	NULL
h	NULL
with	NULL
différent	NULL
vitamin	NULL
D	NULL
;	NULL
metabolites	NULL
(	NULL
10~	NULL
M	NULL
)	NULL
.	NULL

The	NULL
rank	NULL
order	NULL
of	NULL
potency	NULL
(	NULL
1,25	NULL
[	NULL
(	NULL
OH	NULL
]	NULL
;	NULL
D	NULL
;	NULL
>	NULL
1,24,25	NULL
[	NULL
OH	NULL
]	NULL
;	NULL
D	NULL
;	NULL
>	NULL
25	NULL
[	NULL
OH	NULL
]	NULL
JD	NULL
;	NULL
)	NULL
of	NULL
the	NULL
metabolites	NULL
to	NULL
affect	NULL
accumulation	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
paralleled	NULL
the	NULL
affinity	NULL
of	NULL
the	NULL
metabolites	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
cellular	NULL
receptors	NULL
in	NULL
other	NULL
tissues	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Secondly	NULL
,	NULL
1702	NULL
mRNA	NULL
reduction	NULL
(	NULL
%	NULL
)	NULL
0	NULL
17	NULL
52	NULL
67	NULL
80	NULL
“	NULL
..l	NULL
-	NULL
0.9	NULL
kb	NULL
0	NULL
#	NULL
a	NULL
a	NULL
-	NULL
0.9	NULL
kb	NULL
o	NULL
;	NULL
2	NULL
o	NULL
co	NULL
~	NULL
ééééé	NULL
005	NULL
(	NULL
€	NULL
;	NULL
)	NULL
2448	NULL
1.25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
,	NULL
D	NULL
,	NULL
;	NULL
(	NULL
M	NULL
)	NULL
C	NULL
Wp	NULL
w	NULL
«	NULL
-	NULL
m	NULL
-3.5	NULL
kb	NULL
v	NULL
'	NULL
!	NULL
'	NULL

,	NULL
-	NULL
1.4	NULL
kb	NULL
0	NULL
0.5	NULL
6	NULL
24	NULL
48	NULL
(	NULL
h	NULL
)	NULL
Figure	NULL
2	NULL
.	NULL

Modulation	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
levels	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
in	NULL
HTLV-1-immortalized	NULL
T	NULL
lymphocytes	NULL
derived	NULL
from	NULL
a	NULL
normal	NULL
individual	NULL
(	NULL
S-LB1	NULL
)	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Dose-response	NULL
experiments	NULL
.	NULL

S-LB1	NULL
cells	NULL
were	NULL
exposed	NULL
for	NULL
48	NULL
h	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

Analysis	NULL
was	NULL
performed	NULL
by	NULL
Northern	NULL
blot	NULL
technique	NULL
with	NULL
30	NULL
ug	NULL
cytoplasmic	NULL
RNA	NULL
per	NULL
lane	NULL
.	NULL

(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
Time-course	NULL
experiments	NULL
(	NULL
Northern	NULL
blot	NULL
)	NULL
.	NULL

S-LB1	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
various	NULL
durations	NULL
(	NULL
0.5-48	NULL
h	NULL
)	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
10~®	NULL
M	NULL
)	NULL
.	NULL

Each	NULL
lane	NULL
contains	NULL
20	NULL
ug	NULL
RNA	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
the	NULL
same	NULL
samples	NULL
were	NULL
reprobed	NULL
with	NULL
IL-2	NULL
receptor	NULL
cDNA	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Two	NULL
bands	NULL
were	NULL
observed	NULL
at	NULL
1.4	NULL
and	NULL
3.5	NULL
kb	NULL
consistent	NULL
with	NULL
IL-2	NULL
receptor	NULL
mRNA	NULL
.	NULL

Analysis	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

A	NULL
single	NULL
band	NULL
at	NULL
0.9	NULL
kb	NULL
(	NULL
4	NULL
and	NULL
C	NULL
)	NULL
was	NULL
detected	NULL
when	NULL
probed	NULL
with	NULL
GM-CSF	NULL
cDNA	NULL
.	NULL

we	NULL
established	NULL
a	NULL
HTLV-1	NULL
immortalized	NULL
T	NULL
lymphocyte	NULL
cell	NULL
line	NULL
derived	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
vitamin	NULL
D-resistant	NULL
rickets	NULL
type	NULL
II	NULL
(	NULL
Ab-VDR	NULL
)	NULL
.	NULL

Vitamin	NULL
D-resistant	NULL
rickets	NULL
II	NULL
is	NULL
a	NULL
heterogenous	NULL
group	NULL
of	NULL
syndromes	NULL
characterized	NULL
by	NULL
a	NULL
decreased	NULL
or	NULL
absent	NULL
ability	NULL
of	NULL
1,2	NULL
5	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
to	NULL
bind	NULL
to	NULL
its	NULL
cellular	NULL
receptor	NULL
(	NULL
1	NULL
,	NULL
32	NULL
)	NULL
.	NULL

Exposure	NULL
of	NULL
the	NULL
Ab-VDR	NULL
cells	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
10~	NULL
'	NULL
M	NULL
,	NULL
10~'°	NULL
M	NULL
)	NULL
for	NULL
48	NULL
h	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
GM-CSF	NULL
mRNA	NULL
accumulation	NULL
(	NULL
reduction	NULL
of	NULL
mRNA	NULL
of	NULL
~	NULL
15	NULL
%	NULL
compared	NULL
with	NULL
control	NULL
samples	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
densitometry	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
Ab-VDR	NULL
cells	NULL
having	NULL
undetectable	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
cellular	NULL
receptors	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
sucrose	NULL
density	NULL
gradient	NULL
and	NULL
DNA	NULL
chromatography	NULL
analyses	NULL
(	NULL
H.	NULL
P.	NULL
Koeffler	NULL
and	NULL
A.	NULL
W.	NULL
Norman	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

Influence	NULL
of	NULL
IL-2	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
GM-CSF	NULL
by	NULL
S-LBI	NULL
cells	NULL
.	NULL

Previous	NULL
studies	NULL
suggested	NULL
that	NULL
most	NULL
HTLV-1-transformed	NULL
T	NULL
lymphocytes	NULL
do	NULL
not	NULL
synthesize	NULL
IL-2	NULL
(	NULL
33	NULL
)	NULL
.	NULL

We	NULL
probed	NULL
S-LBI	NULL
mRNA	NULL
with	NULL
a	NULL
human	NULL
cDNA	NULL
for	NULL
IL-2	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
C	NULL
)	NULL
.	NULL

The	NULL
PHA-stimulated	NULL
PBL	NULL
were	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
and	NULL
the	NULL
human	NULL
promyelocytic	NULL
cell	NULL
line	NULL
HL-60	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

A	NULL
single	NULL
band	NULL
could	NULL
be	NULL
detected	NULL
at	NULL
0.9	NULL
kb	NULL
in	NULL
PHA-activated	NULL
lymphocytes	NULL
consistent	NULL
with	NULL
IL-2	NULL
mRNA	NULL
(	NULL
24	NULL
)	NULL
.	NULL

However	NULL
,	NULL
no	NULL
IL-2	NULL
mRNA	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
S-LB1	NULL
cells	NULL
and	NULL
yet	NULL
cells	NULL
from	NULL
the	NULL
same	NULL
passage	NULL
were	NULL
regulated	NULL
very	NULL
sensitively	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
4	NULL
)	NULL
.	NULL

Total	NULL
RNA	NULL
synthesis	NULL
by	NULL
S-LBI1	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
[	NULL
``	NULL
*Curidine	NULL
incorporation	NULL
}	NULL
.	NULL

To	NULL
further	NULL
examine	NULL
whether	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
influences	NULL
total	NULL
RNA	NULL
synthesis	NULL
in	NULL
lymphocytes	NULL
,	NULL
we	NULL
exposed	NULL
S-LBI	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
for	NULL
0	NULL
,	NULL
6	NULL
and	NULL
24	NULL
h	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
107	NULL
M	NULL
)	NULL
and	NULL
measured	NULL
[	NULL
'*Cjuridine	NULL
incorporation	NULL
into	NULL
TCA	NULL
precipitable	NULL
counts	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

A	NULL
6-h	NULL
exposure	NULL
A.	NULL
Tobler	NULL
,	NULL
J.	NULL
Gasson	NULL
,	NULL
H.	NULL
Reichel	NULL
,	NULL
A.	NULL
W.	NULL
Norman	NULL
,	NULL
and	NULL
H.	NULL
P.	NULL
Koeffler	NULL
3	NULL
m	NULL
-	NULL
m	NULL
om	NULL
=	NULL
o	NULL
o	NULL
o	NULL
c	NULL
al	NULL
®	NULL
C	NULL
o	NULL
a	NULL
<	NULL
I	NULL
o	NULL
g	NULL
g	NULL
o	NULL
©	NULL
e	NULL
0	NULL
o	NULL
w-	NULL
-	NULL
u	NULL
i	NULL
1	NULL
To	NULL
T	NULL
a	NULL
&	NULL
~	NULL
2	NULL
p	NULL
P	NULL
o	NULL
\_	NULL
_N	NULL
--	NULL
-yz-~	NULL
ou	NULL
-	NULL
Control	NULL
1.25	NULL
(	NULL
OH	NULL
}	NULL
,	NULL
D3	NULL
(	NULL
M	NULL
)	NULL
o	NULL
-	NULL
:	NULL
w	NULL
o	NULL
c	NULL
t	NULL
-J	NULL
E	NULL
_J	NULL
U	NULL
>	NULL
m	NULL
IT	NULL
ﬂ	NULL
-	NULL
0.9	NULL
kb	NULL
Figure	NULL
3	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Regulation	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
by	NULL
different	NULL
vitamin	NULL
D	NULL
metabolites	NULL
in	NULL
S-LB1	NULL
cells	NULL
(	NULL
Northern	NULL
blot	NULL
)	NULL
.	NULL

S-LBI1	NULL
cells	NULL
were	NULL
exposed	NULL
for	NULL
48	NULL
h	NULL
to	NULL
different	NULL
vitamin	NULL
D	NULL
metabolites	NULL
(	NULL
107°	NULL
M	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Regulation	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
the	NULL
HTLV-1-immortalized	NULL
T	NULL
lymphocyte	NULL
line	NULL
Ab-VDR	NULL
which	NULL
was	NULL
derived	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
vitamin	NULL
D-resistant	NULL
rickets	NULL
,	NULL
type	NULL
II	NULL
(	NULL
Northern	NULL
blot	NULL
)	NULL
.	NULL

S-LB1	NULL
cells	NULL
(	NULL
S	NULL
)	NULL
and	NULL
Ab-VDR	NULL
cells	NULL
(	NULL
V	NULL
)	NULL
were	NULL
cultured	NULL
for	NULL
48	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
107°	NULL
and	NULL
10~	NULL
``	NULL
°	NULL
M	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Analysis	NULL
of	NULL
IL-2	NULL
mRNA	NULL
in	NULL
S-LBi	NULL
cells	NULL
(	NULL
Northern	NULL
blot	NULL
)	NULL
.	NULL

Using	NULL
an	NULL
IL-2	NULL
cDNA	NULL
probe	NULL
,	NULL
a	NULL
single	NULL
band	NULL
could	NULL
be	NULL
detected	NULL
from	NULL
RNA	NULL
of	NULL
PHA-activated	NULL
PBL	NULL
at	NULL
0.9	NULL
kb	NULL
(	NULL
Lymph	NULL
,	NULL
positive	NULL
control	NULL
)	NULL
consistent	NULL
with	NULL
IL-2	NULL
mRNA	NULL
;	NULL
RNA	NULL
from	NULL
HL-60	NULL
promyelocytic	NULL
leukemic	NULL
cells	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

Analysis	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
Methods	NULL
.	NULL

Each	NULL
lane	NULL
in	NULL
A4-C	NULL
contains	NULL
30	NULL
ug	NULL
RNA	NULL
.	NULL

A	NULL
single	NULL
band	NULL
at	NULL
0.9	NULL
kb	NULL
(	NULL
4	NULL
and	NULL
B	NULL
)	NULL
was	NULL
detected	NULL
when	NULL
probed	NULL
with	NULL
GM-CSF	NULL
cDNA	NULL
.	NULL

to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
had	NULL
almost	NULL
no	NULL
effect	NULL
on	NULL
RNA	NULL
synthesis	NULL
.	NULL

A	NULL
24-h	NULL
exposure	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
decreased	NULL
the	NULL
incorporation	NULL
of	NULL
[	NULL
'*Cluridine	NULL
TCA	NULL
precipitable	NULL
counts	NULL
by	NULL
~	NULL
33	NULL
%	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
control	NULL
sample	NULL
not	NULL
treated	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

Table	NULL
I	NULL
.	NULL

[	NULL
``	NULL
*C	NULL
]	NULL
Uridine	NULL
Incorporation	NULL
in	NULL
S-LB1	NULL
Cells	NULL
Exposed	NULL
for	NULL
Various	NULL
Durations	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
Experiments	NULL
Mean	NULL
percent	NULL
Time	NULL
exposed	NULL
inhibition	NULL
,	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
No	NULL
.	NULL

1	NULL
No	NULL
.	NULL

2	NULL
nos	NULL
.	NULL

1	NULL
and	NULL
2	NULL
h	NULL
cpm	NULL
x	NULL
10°	NULL
(	NULL
%	NULL
)	NULL
cpm	NULL
X	NULL
10	NULL
``	NULL
(	NULL
%	NULL
)	NULL
0	NULL
(	NULL
control	NULL
)	NULL
9.8+0.17	NULL
(	NULL
0	NULL
)	NULL
1.26+0.03	NULL
(	NULL
0	NULL
)	NULL
0	NULL
6	NULL
9.6+0.04	NULL
(	NULL
2	NULL
)	NULL
1.17+0.03	NULL
(	NULL
6	NULL
)	NULL
4	NULL
24	NULL
6.4+0.04	NULL
(	NULL
33	NULL
)	NULL
0.85+0.03	NULL
(	NULL
32	NULL
)	NULL
33	NULL
[	NULL
'*C	NULL
]	NULL
Uridine	NULL
incorporation	NULL
as	NULL
a	NULL
measurement	NULL
of	NULL
RNA	NULL
metabolism	NULL
.	NULL

S-LBI1	NULL
cells	NULL
(	NULL
1	NULL
%	NULL
10°/ml	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
ethanol	NULL
control	NULL
(	NULL
<	NULL
0.01	NULL
%	NULL
ethanol	NULL
)	NULL
or	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
107°	NULL
M	NULL
)	NULL
.	NULL

Results	NULL
represent	NULL
mean+SD	NULL
of	NULL
quadruplicate	NULL
cultures	NULL
of	NULL
two	NULL
independent	NULL
experiments	NULL
(	NULL
Nos	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Numbers	NULL
in	NULL
parentheses	NULL
denote	NULL
percentage	NULL
of	NULL
inhibition	NULL
as	NULL
compared	NULL
with	NULL
control	NULL
sample	NULL
treated	NULL
with	NULL
no	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

Analysis	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
Methods	NULL
.	NULL

Colony-stimulating	NULL
Factor	NULL
Regulation	NULL
by	NULL
1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
Proliferation	NULL
studies	NULL
(	NULL
[	NULL
°H	NULL
thymidine	NULL
incorporation	NULL
)	NULL
.	NULL

We	NULL
measured	NULL
the	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
10~	NULL
'	NULL
M	NULL
)	NULL
on	NULL
PHA-activated	NULL
PBL	NULL
by	NULL
measuring	NULL
[	NULL
°HJthymidine	NULL
incorporation	NULL
.	NULL

After	NULL
48	NULL
h	NULL
in	NULL
culture	NULL
,	NULL
PHA-activated	NULL
PBL	NULL
incorporated	NULL
11,911+4,446	NULL
cpm/	NULL
10®	NULL
cells	NULL
.	NULL

Treatment	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
10~	NULL
'	NULL
M	NULL
)	NULL
for	NULL
48	NULL
h	NULL
resulted	NULL
in	NULL
a	NULL
statistically	NULL
insignificant	NULL
(	NULL
P	NULL
>	NULL
0.5	NULL
)	NULL
decrease	NULL
of	NULL
incorporation	NULL
into	NULL
PBL	NULL
(	NULL
8,728+2,097	NULL
cpm/10®	NULL
cells	NULL
)	NULL
,	NULL
representing	NULL
a	NULL
16.7	NULL
%	NULL
inhibition	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
control	NULL
samples	NULL
not	NULL
treated	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
.	NULL

The	NULL
results	NULL
represent	NULL
the	NULL
mean+SD	NULL
for	NULL
nine	NULL
incubations	NULL
.	NULL

Discussion	NULL
We	NULL
report	NULL
in	NULL
the	NULL
present	NULL
in	NULL
vitro	NULL
study	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
the	NULL
most	NULL
active	NULL
metabolite	NULL
of	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
is	NULL
a	NULL
potent	NULL
inhibitor	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
hematopoietic	NULL
growth	NULL
factor	NULL
GM-CSF	NULL
in	NULL
PHA-activated	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
PBL	NULL
)	NULL
.	NULL

The	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
regulated	NULL
both	NULL
protein	NULL
and	NULL
mRNA	NULL
accumulation	NULL
of	NULL
GM-CSF	NULL
;	NULL
and	NULL
this	NULL
down-regulation	NULL
occurred	NULL
at	NULL
concentrations	NULL
close	NULL
to	NULL
those	NULL
in	NULL
vivo	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
recent	NULL
reports	NULL
that	NULL
activated	NULL
macrophages	NULL
synthesize	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
,	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
further	NULL
indicate	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
might	NULL
interact	NULL
with	NULL
GM-CSF	NULL
production	NULL
at	NULL
a	NULL
local	NULL
level	NULL
.	NULL

Our	NULL
time-response	NULL
studies	NULL
indicate	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
can	NULL
influence	NULL
GM-CSF	NULL
expression	NULL
by	NULL
PBL	NULL
also	NULL
in	NULL
later	NULL
stages	NULL
of	NULL
mitogenesis	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
E	NULL
)	NULL
.	NULL

The	NULL
concentrations	NULL
of	NULL
1,2	NULL
5	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
achieving	NULL
half-maximal	NULL
response	NULL
(	NULL
EDs	NULL
,	NULL
)	NULL
were	NULL
5	NULL
xX	NULL
107	NULL
``	NULL
M	NULL
and	NULL
5	NULL
X	NULL
10~	NULL
``	NULL
°	NULL
M	NULL
for	NULL
GM-CSF	NULL
mRNA	NULL
levels	NULL
and	NULL
GM-CSF	NULL
protein	NULL
activity	NULL
,	NULL
respectively	NULL
.	NULL

These	NULL
differences	NULL
in	NULL
the	NULL
EDs	NULL
,	NULL
can	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
greater	NULL
sensitivity	NULL
and	NULL
specificity	NULL
of	NULL
the	NULL
RNA	NULL
blot	NULL
technique	NULL
compared	NULL
with	NULL
the	NULL
clonogenic	NULL
assay	NULL
in	NULL
soft	NULL
agar	NULL
.	NULL

In	NULL
the	NULL
clonogenic	NULL
assay	NULL
,	NULL
CM	NULL
from	NULL
PHA-stimulated	NULL
lymphocytes	NULL
was	NULL
used	NULL
which	NULL
,	NULL
besides	NULL
GM-CSF	NULL
,	NULL
also	NULL
contains	NULL
an	NULL
admixture	NULL
of	NULL
other	NULL
growth	NULL
factors	NULL
,	NULL
including	NULL
interleukin	NULL
3	NULL
and	NULL
other	NULL
lymphokines	NULL
.	NULL

These	NULL
additional	NULL
factors	NULL
may	NULL
have	NULL
decreased	NULL
both	NULL
the	NULL
sensitivity	NULL
and	NULL
specificity	NULL
of	NULL
the	NULL
clonogenic	NULL
assay	NULL
.	NULL

Similar	NULL
to	NULL
PBL	NULL
,	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
sensitively	NULL
inhibited	NULL
mRNA	NULL
accumulation	NULL
of	NULL
GM-CSF	NULL
by	NULL
the	NULL
HTLV-1	NULL
immortalized	NULL
T	NULL
lymphocytes	NULL
(	NULL
S-LB1	NULL
)	NULL
derived	NULL
from	NULL
a	NULL
normal	NULL
individual	NULL
(	NULL
19	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
4	NULL
)	NULL
.	NULL

The	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
did	NULL
not	NULL
markedly	NULL
affect	NULL
mRNA	NULL
levels	NULL
for	NULL
the	NULL
IL-2	NULL
receptor	NULL
in	NULL
either	NULL
the	NULL
PHA-activated	NULL
PBL	NULL
or	NULL
S-LBI1	NULL
cells	NULL
which	NULL
constitutively	NULL
produce	NULL
high	NULL
levels	NULL
of	NULL
IL-2	NULL
receptors	NULL
(	NULL
Figs	NULL
.	NULL

1	NULL
C	NULL
,	NULL
2	NULL
C	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
does	NULL
not	NULL
non-specifically	NULL
decrease	NULL
levels	NULL
of	NULL
mRNA	NULL
in	NULL
lymphocytes	NULL
.	NULL

The	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
inhibited	NULL
total	NULL
cellular	NULL
RNA	NULL
synthesis	NULL
in	NULL
S-LBI1	NULL
cells	NULL
as	NULL
determined	NULL
by	NULL
incorporation	NULL
of	NULL
{	NULL
'	NULL
``	NULL
CJuridine	NULL
into	NULL
TCA	NULL
precipitable	NULL
counts	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

This	NULL
inhibition	NULL
of	NULL
total	NULL
RNA	NULL
,	NULL
however	NULL
,	NULL
was	NULL
much	NULL
less	NULL
pronounced	NULL
and	NULL
less	NULL
rapid	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
decrease	NULL
in	NULL
GM-CSF	NULL
mRNA	NULL
in	NULL
the	NULL
same	NULL
cells	NULL
(	NULL
4	NULL
and	NULL
52	NULL
%	NULL
inhibition	NULL
,	NULL
respectively	NULL
,	NULL
after	NULL
exposure	NULL
for	NULL
6h	NULL
to	NULL
1,25	NULL
[	NULL
OH	NULL
]	NULL
;	NULL
D	NULL
;	NULL
[	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
,	NULL
Table	NULL
I	NULL
]	NULL
)	NULL
.	NULL

Several	NULL
recent	NULL
reports	NULL
suggested	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
may	NULL
be	NULL
capable	NULL
of	NULL
immunoregulation	NULL
similar	NULL
to	NULL
the	NULL
glucocorticoids	NULL
.	NULL

Tsoukas	NULL
et	NULL
al	NULL
.	NULL

showed	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
inhibited	NULL
the	NULL
lymphocyte	NULL
growth-promoting	NULL
factor	NULL
IL-2	NULL
by	NULL
PBL	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Studies	NULL
using	NULL
different	NULL
vitamin	NULL
D	NULL
;	NULL
metabolites	NULL
suggested	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
probably	NULL
mediated	NULL
by	NULL
a	NULL
specific	NULL
receptor	NULL
.	NULL

Likewise	NULL
,	NULL
Rigby	NULL
et	NULL
al	NULL
.	NULL

demonstrated	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
a	NULL
potent	NULL
inhibitor	NULL
of	NULL
PHA-induced	NULL
lymphocyte	NULL
proliferation	NULL
,	NULL
achieving	NULL
a	NULL
70	NULL
%	NULL
inhibition	NULL
of	NULL
incorporation	NULL
after	NULL
72	NULL
h	NULL
in	NULL
culture	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Another	NULL
study	NULL
also	NULL
showed	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
1703	NULL
inhibited	NULL
the	NULL
proliferation	NULL
and	NULL
IL-2	NULL
protein	NULL
production	NULL
by	NULL
helper	NULL
T	NULL
lymphocytes	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
decreased	NULL
the	NULL
antigen-induced	NULL
proliferation	NULL
and	NULL
IL-2	NULL
protein	NULL
synthesis	NULL
by	NULL
cloned	NULL
Ta-restricted	NULL
T	NULL
cell	NULL
hybridomas	NULL
after	NULL
24	NULL
h	NULL
in	NULL
culture	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
studies	NULL
revealed	NULL
a	NULL
possible	NULL
immunoregulatory	NULL
role	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
that	NULL
has	NULL
not	NULL
previously	NULL
been	NULL
appreciated	NULL
.	NULL

The	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptors	NULL
are	NULL
not	NULL
present	NULL
in	NULL
resting	NULL
T	NULL
lymphocytes	NULL
,	NULL
but	NULL
do	NULL
appear	NULL
24	NULL
h	NULL
after	NULL
mitogenic	NULL
stimulation	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
HTLV-1-immortalized	NULL
T-cell	NULL
lines	NULL
constitutively	NULL
express	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
receptors	NULL
.	NULL

Our	NULL
experiments	NULL
using	NULL
different	NULL
vitamin	NULL
D	NULL
;	NULL
metabolites	NULL
suggest	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
the	NULL
GM-CSF	NULL
expression	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
most	NULL
likely	NULL
mediated	NULL
through	NULL
specific	NULL
cellular	NULL
receptors	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

The	NULL
potency	NULL
of	NULL
these	NULL
compounds	NULL
to	NULL
reduce	NULL
mRNA	NULL
levels	NULL
of	NULL
GM-CSF	NULL
paralleled	NULL
their	NULL
known	NULL
affinity	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
specific	NULL
cellular	NULL
receptor	NULL
in	NULL
other	NULL
tissues	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
our	NULL
results	NULL
are	NULL
in	NULL
accordance	NULL
with	NULL
the	NULL
reported	NULL
dissociation	NULL
constant	NULL
of	NULL
3.8	NULL
X	NULL
10~'°	NULL
M	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
by	NULL
PHA-activated	NULL
PBL	NULL
(	NULL
3	NULL
)	NULL
.	NULL

A	NULL
more	NULL
direct	NULL
evidence	NULL
for	NULL
this	NULL
assumption	NULL
of	NULL
a	NULL
receptor-mediated	NULL
mechanism	NULL
relies	NULL
on	NULL
our	NULL
study	NULL
using	NULL
a	NULL
HTLV-1-immortalized	NULL
T	NULL
lymphocyte	NULL
line	NULL
(	NULL
Ab-VDR	NULL
)	NULL
that	NULL
was	NULL
derived	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
vitamin	NULL
D-resistant	NULL
rickets	NULL
type	NULL
II	NULL
.	NULL

Exposure	NULL
of	NULL
Ab-VDR	NULL
cells	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
resulted	NULL
in	NULL
only	NULL
a	NULL
small	NULL
decrease	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
levels	NULL
compared	NULL
with	NULL
the	NULL
marked	NULL
decrease	NULL
in	NULL
S-LB1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
our	NULL
observation	NULL
that	NULL
Ab-VDR	NULL
cells	NULL
have	NULL
undetectable	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptors	NULL
,	NULL
whereas	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
-sen-sitive	NULL
S-LBI1	NULL
cells	NULL
display	NULL
13	NULL
fmol	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptors/10®	NULL
cells	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
sucrose	NULL
density	NULL
gradient	NULL
and	NULL
DNA	NULL
chromatography	NULL
analyses	NULL
(	NULL
H.	NULL
P.	NULL
Koeffler	NULL
and	NULL
A.	NULL
W.	NULL
Norman	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
Ab-VDR	NULL
cells	NULL
responded	NULL
at	NULL
all	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
suggests	NULL
that	NULL
either	NULL
these	NULL
cells	NULL
have	NULL
a	NULL
low	NULL
number	NULL
of	NULL
receptors	NULL
not	NULL
detectable	NULL
by	NULL
the	NULL
present	NULL
techniques	NULL
or	NULL
very	NULL
high	NULL
concentrations	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
can	NULL
affect	NULL
all	NULL
cells	NULL
independent	NULL
of	NULL
expression	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptors	NULL
.	NULL

Studies	NULL
are	NULL
currently	NULL
under	NULL
way	NULL
to	NULL
analyze	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptors	NULL
in	NULL
these	NULL
cells	NULL
by	NULL
using	NULL
a	NULL
specific	NULL
cDNA	NULL
probe	NULL
for	NULL
this	NULL
hormone	NULL
receptor	NULL
.	NULL

Koren	NULL
et	NULL
al	NULL
.	NULL

recently	NULL
reported	NULL
that	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
vitamin	NULL
D-resistant	NULL
rickets	NULL
type	NULL
II	NULL
do	NULL
not	NULL
express	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptors	NULL
,	NULL
even	NULL
after	NULL
mitogenic	NULL
stimulation	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
proliferation	NULL
of	NULL
these	NULL
lymphocytes	NULL
could	NULL
not	NULL
be	NULL
inhibited	NULL
after	NULL
a	NULL
72-h	NULL
exposure	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
normal	NULL
cells	NULL
.	NULL

Because	NULL
prior	NULL
studies	NULL
showed	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
inhibited	NULL
the	NULL
production	NULL
of	NULL
IL-2	NULL
(	NULL
9	NULL
,	NULL
10	NULL
,	NULL
34	NULL
)	NULL
,	NULL
we	NULL
questioned	NULL
whether	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
might	NULL
mediate	NULL
its	NULL
inhibitory	NULL
effect	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
GM-CSF	NULL
indirectly	NULL
through	NULL
a	NULL
down-regulation	NULL
of	NULL
IL-2	NULL
production	NULL
.	NULL

Addition	NULL
of	NULL
very	NULL
high	NULL
concentrations	NULL
of	NULL
IL-2	NULL
(	NULL
200	NULL
ng/	NULL
ml	NULL
)	NULL
slightly	NULL
abrogated	NULL
but	NULL
did	NULL
not	NULL
reverse	NULL
the	NULL
inhibition	NULL
of	NULL
GM-CSF	NULL
protein	NULL
production	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
PBL	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
4	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
S-LB1	NULL
cells	NULL
did	NULL
not	NULL
express	NULL
IL-2	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
C	NULL
)	NULL
.	NULL

This	NULL
T-cell	NULL
line	NULL
,	NULL
therefore	NULL
,	NULL
provided	NULL
an	NULL
unusual	NULL
tool	NULL
to	NULL
study	NULL
our	NULL
assumption	NULL
of	NULL
a	NULL
possible	NULL
IL-2-indepen-dent	NULL
regulation	NULL
of	NULL
GM-CSF	NULL
expression	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

Our	NULL
dose-response	NULL
and	NULL
time-course	NULL
experiments	NULL
clearly	NULL
showed	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
sensitively	NULL
inhibited	NULL
GM-CSF	NULL
mRNA	NULL
levels	NULL
by	NULL
S-LBI	NULL
cells	NULL
in	NULL
an	NULL
IL-2-free	NULL
system	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
4	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
our	NULL
experiments	NULL
suggest	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
can	NULL
regulate	NULL
independently	NULL
of	NULL
IL-2	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
lymphokine	NULL
in	NULL
transformed	NULL
T	NULL
lymphocytes	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
normal	NULL
human	NULL
PBL	NULL
seems	NULL
to	NULL
be	NULL
mostly	NULL
but	NULL
not	NULL
totally	NULL
independent	NULL
from	NULL
IL-2	NULL
.	NULL

Our	NULL
study	NULL
using	NULL
[	NULL
°HJthymidine	NULL
showed	NULL
no	NULL
significant	NULL
inhibition	NULL
of	NULL
the	NULL
proliferation	NULL
of	NULL
PHA-activated	NULL
lymphocytes	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

Other	NULL
investigators	NULL
,	NULL
however	NULL
,	NULL
found	NULL
a	NULL
marked	NULL
inhibition	NULL
of	NULL
the	NULL
lymphocyte	NULL
proliferation	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
as	NULL
mentioned	NULL
above	NULL
(	NULL
8	NULL
,	NULL
9	NULL
,	NULL
11	NULL
)	NULL
.	NULL

This	NULL
discrepancy	NULL
might	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
PBL	NULL
in	NULL
the	NULL
other	NULL
experiments	NULL
were	NULL
cultured	NULL
for	NULL
72	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PHA	NULL
and	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
whereas	NULL
in	NULL
our	NULL
study	NULL
,	NULL
[	NULL
}	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
was	NULL
determined	NULL
at	NULL
48	NULL
h	NULL
of	NULL
culture	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
GM-CSF	NULL
production	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
not	NULL
necessarily	NULL
linked	NULL
to	NULL
its	NULL
reported	NULL
antiproliferative	NULL
properties	NULL
.	NULL

How	NULL
does	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
regulate	NULL
the	NULL
expression	NULL
of	NULL
GM-CSF	NULL
?	NULL

In	NULL
the	NULL
case	NULL
of	NULL
glucocorticoids	NULL
,	NULL
studies	NULL
showed	NULL
that	NULL
mouse	NULL
mammary	NULL
tumor	NULL
virus	NULL
DNA	NULL
contains	NULL
regions	NULL
to	NULL
which	NULL
the	NULL
glucocorticoid-receptor	NULL
complex	NULL
can	NULL
specifically	NULL
bind	NULL
.	NULL

Transcription	NULL
is	NULL
directly	NULL
stimulated	NULL
by	NULL
interaction	NULL
of	NULL
the	NULL
glucocorticoid-receptor	NULL
complex	NULL
with	NULL
DNA	NULL
sequences	NULL
adjacent	NULL
to	NULL
the	NULL
promoter	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
35	NULL
)	NULL
.	NULL

In	NULL
a	NULL
parallel	NULL
fashion	NULL
to	NULL
the	NULL
glucocorticoids	NULL
,	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptor	NULL
complex	NULL
might	NULL
specifically	NULL
bind	NULL
to	NULL
certain	NULL
regions	NULL
of	NULL
DNA	NULL
and	NULL
inhibit	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
GM-CSF	NULL
gene	NULL
either	NULL
directly	NULL
or	NULL
via	NULL
a	NULL
transacting	NULL
mechanism	NULL
.	NULL

Vanice	NULL
et	NULL
al	NULL
.	NULL

,	NULL
however	NULL
,	NULL
recently	NULL
reported	NULL
that	NULL
dexamethasone	NULL
regulated	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
alpha-1-acid	NULL
glycoprotein	NULL
at	NULL
the	NULL
posttranscriptional	NULL
level	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Preliminary	NULL
experiments	NULL
by	NULL
us	NULL
using	NULL
in	NULL
vitro	NULL
nuclear	NULL
run-on	NULL
assays	NULL
suggest	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
affects	NULL
the	NULL
stability	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
our	NULL
study	NULL
shows	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
inhibits	NULL
sensitively	NULL
the	NULL
expression	NULL
of	NULL
GM-CSF	NULL
by	NULL
PBL	NULL
and	NULL
a	NULL
HTLV-1	NULL
immortalized	NULL
T	NULL
lymphocyte	NULL
line	NULL
at	NULL
the	NULL
mRNA	NULL
level	NULL
.	NULL

This	NULL
down-regulation	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
specific	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptor	NULL
and	NULL
can	NULL
further	NULL
occur	NULL
independently	NULL
of	NULL
IL-2	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
might	NULL
be	NULL
important	NULL
as	NULL
a	NULL
regulatory	NULL
hormone	NULL
in	NULL
hematopoiesis	NULL
.	NULL

Acknowledgments	NULL
We	NULL
would	NULL
like	NULL
to	NULL
thank	NULL
Suzanne	NULL
Bookstaver	NULL
and	NULL
Regina	NULL
Simon	NULL
for	NULL
their	NULL
excellent	NULL
secretarial	NULL
help	NULL
,	NULL
Dr.	NULL
S.	NULL
Clarke	NULL
for	NULL
generously	NULL
providing	NULL
the	NULL
IL-2	NULL
cDNA	NULL
,	NULL
Dr.	NULL
T.	NULL
Nikaido	NULL
for	NULL
kindly	NULL
providing	NULL
the	NULL
IL-2	NULL
receptor	NULL
cDNA	NULL
,	NULL
Dr.	NULL
J.	NULL
Besemer	NULL
for	NULL
generously	NULL
providing	NULL
recombinant	NULL
IL-2	NULL
,	NULL
and	NULL
Dr.	NULL
M.	NULL
Uskokovic	NULL
for	NULL
kindly	NULL
providing	NULL
the	NULL
vitamin	NULL
D	NULL
metabolites	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
United	NULL
States	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
CA-26038	NULL
,	NULL
CA-32737	NULL
,	NULL
CA-33936	NULL
,	NULL
CA-30512	NULL
,	NULL
and	NULL
CA-32428	NULL
,	NULL
the	NULL
Dr.	NULL
Murray	NULL
Geisler	NULL
Memorial	NULL
Fund	NULL
,	NULL
the	NULL
Louis	NULL
Fagin	NULL
Leukemia	NULL
Research	NULL
Foundation	NULL
(	NULL
Dr.	NULL
Koeffier	NULL
)	NULL
,	NULL
AM-14,750-014	NULL
(	NULL
Dr.	NULL
Koeffler	NULL
and	NULL
Dr.	NULL
Nor-man	NULL
)	NULL
,	NULL
the	NULL
Deutsche	NULL
Forschungsgemeinschaft	NULL
(	NULL
Dr.	NULL
Reichel	NULL
)	NULL
,	NULL
CA-40136	NULL
(	NULL
Dr.	NULL
Gasson	NULL
)	NULL
,	NULL
and	NULL
the	NULL
Swiss	NULL
and	NULL
Bernese	NULL
Cancer	NULL
Ligues	NULL
(	NULL
Dr.	NULL
Tobler	NULL
)	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Bell	NULL
,	NULL
N.	NULL
H.	NULL
1985	NULL
.	NULL

Vitamin	NULL
D-endocrine	NULL
system	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

76:1-6	NULL
.	NULL

2	NULL
.	NULL

Manolagas	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
and	NULL
L.	NULL
J.	NULL
Deftos	NULL
.	NULL

1984	NULL
.	NULL

The	NULL
vitamin	NULL
D	NULL
endocrine	NULL
system	NULL
and	NULL
the	NULL
hematolymphopoietic	NULL
tissue	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

100:144-146	NULL
.	NULL

3	NULL
.	NULL

Provvedini	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
C.	NULL
D.	NULL
Tsoukas	NULL
,	NULL
L.	NULL
J.	NULL
Deftos	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Manolagas	NULL
.	NULL

1983	NULL
.	NULL

1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
receptors	NULL
in	NULL
human	NULL
leukocytes	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

221	NULL
:	NULL
1181-1183	NULL
.	NULL

4	NULL
.	NULL

Bhalla	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
E.	NULL
P.	NULL
Amento	NULL
,	NULL
T.	NULL
L.	NULL
Clemens	NULL
,	NULL
M.	NULL
P.	NULL
Holick	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Krane	NULL
.	NULL

1983	NULL
.	NULL

Specific	NULL
high-affinity	NULL
receptors	NULL
for	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
:	NULL
presence	NULL
in	NULL
monocytes	NULL
and	NULL
induction	NULL
in	NULL
T	NULL
lymphocytes	NULL
following	NULL
activation	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

&	NULL
Metab	NULL
.	NULL

57:1308-1310	NULL
.	NULL

1704	NULL
__	NULL
A.	NULL
Tobler	NULL
,	NULL
J.	NULL
Gasson	NULL
,	NULL
H.	NULL
Reichel	NULL
,	NULL
A.	NULL
W.	NULL
Norman	NULL
,	NULL
and	NULL
H.	NULL
P.	NULL
Koeffler	NULL
5	NULL
.	NULL

Koeffler	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
T.	NULL
Amatruda	NULL
,	NULL
N.	NULL
Ikekawa	NULL
,	NULL
Y.	NULL
Kobayashi	NULL
,	NULL
and	NULL
H.	NULL
F.	NULL
DeLuca	NULL
.	NULL

1984	NULL
.	NULL

Induction	NULL
of	NULL
macrophage	NULL
differentiation	NULL
of	NULL
human	NULL
normal	NULL
and	NULL
leukemic	NULL
myeloid	NULL
stem	NULL
cells	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
and	NULL
its	NULL
fluorinated	NULL
analogs	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

44:5624-5628	NULL
.	NULL

6	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
H.	NULL
P.	NULL
Koeffler	NULL
,	NULL
C.	NULL
A.	NULL
Donaldson	NULL
,	NULL
J.	NULL
W.	NULL
Pike	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Haussler	NULL
.	NULL

1984	NULL
.	NULL

1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
-induced	NULL
differentiation	NULL
in	NULL
a	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL-60	NULL
)	NULL
:	NULL
receptor-mediated	NULL
maturation	NULL
to	NULL
macrophage-like	NULL
cells	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

98:391-398	NULL
.	NULL

7	NULL
.	NULL

Munker	NULL
,	NULL
R.	NULL
,	NULL
A.	NULL
W.	NULL
Norman	NULL
,	NULL
and	NULL
H.	NULL
P.	NULL
Koeffler	NULL
.	NULL

1986	NULL
.	NULL

Vitamin	NULL
D	NULL
compounds	NULL
:	NULL
effects	NULL
on	NULL
clonal	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
human	NULL
myeloid	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

78:424-430	NULL
.	NULL

8	NULL
.	NULL

Lemire	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
J.	NULL
S.	NULL
Adams	NULL
,	NULL
V.	NULL
Kermani-Arab	NULL
,	NULL
A.	NULL
C.	NULL
Bakke	NULL
,	NULL
R.	NULL
Sakai	NULL
,	NULL
and	NULL
S	NULL
$	NULL
.	NULL

C.	NULL
Jordan	NULL
.	NULL

1985	NULL
.	NULL

1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
suppresses	NULL
human	NULL
T	NULL
helper/inducer	NULL
lymphocyte	NULL
activity	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

134	NULL
:	NULL
3032-3035	NULL
.	NULL

9	NULL
.	NULL

Rigby	NULL
,	NULL
W.	NULL
F.	NULL
C.	NULL
,	NULL
T.	NULL
Stacy	NULL
,	NULL
and	NULL
M.	NULL
W.	NULL
Fanger	NULL
.	NULL

1984	NULL
.	NULL

Inhibition	NULL
of	NULL
T	NULL
lymphocyte	NULL
mitogenesis	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
(	NULL
calcitriol	NULL
)	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

74:1451-1455	NULL
.	NULL

10	NULL
.	NULL

Tsoukas	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
D.	NULL
M.	NULL
Provvedini	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Manolagas	NULL
.	NULL

1984	NULL
.	NULL

1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
:	NULL
a	NULL
novel	NULL
immunoregulatory	NULL
hormone	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

224:1438-1440	NULL
.	NULL

11	NULL
.	NULL

Bhalla	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
E.	NULL
P.	NULL
Amento	NULL
,	NULL
B.	NULL
Serog	NULL
,	NULL
and	NULL
L.	NULL
H.	NULL
Glimcher	NULL
.	NULL

1984	NULL
.	NULL

1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
inhibits	NULL
antigen-induced	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

113	NULL
;	NULL
:1748-1754	NULL
.	NULL

12	NULL
.	NULL

Adams	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Gacad	NULL
.	NULL

1985	NULL
.	NULL

Characterization	NULL
of	NULL
1a-hydroxylation	NULL
of	NULL
vitamin	NULL
D	NULL
;	NULL
sterols	NULL
by	NULL
cultured	NULL
alveolar	NULL
macrophages	NULL
from	NULL
patients	NULL
with	NULL
sarcoidosis	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

161:755-765	NULL
.	NULL

13	NULL
.	NULL

Koeffler	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
H.	NULL
Reichel	NULL
,	NULL
J.	NULL
E.	NULL
Bishop	NULL
,	NULL
and	NULL
A.	NULL
W.	NULL
Norman	NULL
.	NULL

1985.	NULL
y-Interferon	NULL
stimulates	NULL
production	NULL
of	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
by	NULL
normal	NULL
human	NULL
macrophage	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

127	NULL
:	NULL
596-603	NULL
.	NULL

14	NULL
.	NULL

Cantrel	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
D.	NULL
Anderson	NULL
,	NULL
D.	NULL
P.	NULL
Cerretti	NULL
,	NULL
V.	NULL
Price	NULL
,	NULL
K.	NULL
Mc-Kereghan	NULL
,	NULL
R.	NULL
J.	NULL
Tushinski	NULL
,	NULL
D.	NULL
Y.	NULL
Mochizuki	NULL
,	NULL
A.	NULL
Larsen	NULL
,	NULL
K.	NULL
Grabstein	NULL
,	NULL
S.	NULL
Gillis	NULL
,	NULL
and	NULL
D.	NULL
Cosman	NULL
.	NULL

1985	NULL
.	NULL

Cloning	NULL
,	NULL
sequence	NULL
,	NULL
and	NULL
expression	NULL
of	NULL
a	NULL
human	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

82:6250-6254	NULL
.	NULL

15	NULL
.	NULL

Wong	NULL
,	NULL
G.	NULL
G.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
S.	NULL
Witek	NULL
,	NULL
P.	NULL
A.	NULL
Temple	NULL
,	NULL
K.	NULL
M.	NULL
Wilkens	NULL
,	NULL
A.	NULL
C.	NULL
Leary	NULL
,	NULL
D.	NULL
P.	NULL
Luxenberg	NULL
,	NULL
S.	NULL
S.	NULL
Jones	NULL
,	NULL
E.	NULL
L.	NULL
Brown	NULL
,	NULL
R.	NULL
M.	NULL
Kay	NULL
,	NULL
E.	NULL
C.	NULL
Orr	NULL
,	NULL
C.	NULL
H.	NULL
Shoemaker	NULL
,	NULL
D.	NULL
W.	NULL
Golde	NULL
,	NULL
R.	NULL
J.	NULL
Kaufman	NULL
,	NULL
R.	NULL
M.	NULL
Hewick	NULL
,	NULL
E.	NULL
A.	NULL
Wang	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Clark	NULL
.	NULL

1985	NULL
.	NULL

Human	NULL
GM-CSF	NULL
:	NULL
molecular	NULL
cloning	NULL
of	NULL
the	NULL
complementary	NULL
DNA	NULL
and	NULL
purification	NULL
of	NULL
the	NULL
natural	NULL
and	NULL
recombinant	NULL
proteins	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

228:8	NULL
10-815	NULL
.	NULL

16	NULL
.	NULL

Tomonaga	NULL
,	NULL
M.	NULL
,	NULL
D.	NULL
W.	NULL
Golde	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Gasson	NULL
.	NULL

1986	NULL
.	NULL

Biosynthetic	NULL
(	NULL
recombinant	NULL
)	NULL
human	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
:	NULL
effect	NULL
on	NULL
normal	NULL
bone	NULL
marrow	NULL
and	NULL
leukemic	NULL
cell	NULL
lines	NULL
.	NULL

Blood	NULL
.	NULL

67	NULL
:	NULL
31-36	NULL
.	NULL

17	NULL
.	NULL

Sieff	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
S.	NULL
G.	NULL
Emerson	NULL
,	NULL
R.	NULL
E.	NULL
Donahue	NULL
,	NULL
D.	NULL
G.	NULL
Nathan	NULL
,	NULL
E.	NULL
A.	NULL
Wang	NULL
,	NULL
G.	NULL
G.	NULL
Wong	NULL
,	NULL
and	NULL
S	NULL
$	NULL
.	NULL

C.	NULL
Clark	NULL
.	NULL

1985	NULL
.	NULL

Recombinant	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
:	NULL
a	NULL
multilineage	NULL
hemato-poietin	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

230:1171-1173	NULL
.	NULL

18	NULL
.	NULL

Gasson	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
R.	NULL
H.	NULL
Weissbart	NULL
,	NULL
S.	NULL
E.	NULL
Kaufman	NULL
,	NULL
S.	NULL
C.	NULL
Clark	NULL
,	NULL
R.	NULL
M.	NULL
Hewick	NULL
,	NULL
G.	NULL
G.	NULL
Wong	NULL
,	NULL
and	NULL
D.	NULL
W.	NULL
Golde	NULL
.	NULL

1984	NULL
.	NULL

Purified	NULL
human	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
:	NULL
direct	NULL
action	NULL
on	NULL
neutrophils	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

226:1339-1342	NULL
.	NULL

19	NULL
.	NULL

Weisbart	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
D.	NULL
W.	NULL
Golde	NULL
,	NULL
S.	NULL
C.	NULL
Clark	NULL
,	NULL
G.	NULL
G.	NULL
Wong	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Gasson	NULL
.	NULL

1985	NULL
.	NULL

Human	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
is	NULL
a	NULL
neutrophil	NULL
activator	NULL
.	NULL

Nature	NULL
.	NULL

314:361-363	NULL
.	NULL

Colony-stimulating	NULL
Factor	NULL
Regulation	NULL
by	NULL
1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
20	NULL
.	NULL

Koeffler	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
,	NULL
and	NULL
D.	NULL
W.	NULL
Golde	NULL
.	NULL

1984	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
novel	NULL
HTLV-infected	NULL
cell	NULL
line	NULL
.	NULL

Blood	NULL
.	NULL

64:482-490	NULL
.	NULL

21	NULL
.	NULL

Colline	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
R.	NULL
E.	NULL
Gallagher	NULL
.	NULL

1977	NULL
.	NULL

Continuous	NULL
growth	NULL
and	NULL
differentiation	NULL
of	NULL
human	NULL
myeloid	NULL
leukemic	NULL
cells	NULL
in	NULL
suspension	NULL
culture	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

270:347-349	NULL
.	NULL

22	NULL
.	NULL

Koeffler	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
and	NULL
D.	NULL
W.	NULL
Golde	NULL
.	NULL

1978	NULL
.	NULL

Acute	NULL
myelogenous	NULL
leukemia	NULL
:	NULL
a	NULL
human	NULL
cell	NULL
line	NULL
responsive	NULL
to	NULL
colony-stimulating	NULL
activity	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

200:1153-1154	NULL
.	NULL

23	NULL
.	NULL

Golde	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
S.	NULL
G.	NULL
Quan	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Cline	NULL
.	NULL

1978	NULL
.	NULL

Human	NULL
T	NULL
lymphocyte	NULL
cell	NULL
line	NULL
producing	NULL
colony-stimulating	NULL
activity	NULL
.	NULL

Blood	NULL
.	NULL

52	NULL
:	NULL
1068-1072	NULL
.	NULL

24	NULL
.	NULL

Clark	NULL
,	NULL
S.	NULL
,	NULL
S.	NULL
K.	NULL
Arya	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
M.	NULL
Matsumoto-Kobayashi	NULL
,	NULL
R.	NULL
M.	NULL
Kay	NULL
,	NULL
R.	NULL
J.	NULL
Kaufman	NULL
,	NULL
E.	NULL
L.	NULL
Brown	NULL
,	NULL
C.	NULL
Shoemaker	NULL
,	NULL
T.	NULL
Copeland	NULL
,	NULL
S.	NULL
Oroszlan	NULL
,	NULL
K.	NULL
Smith	NULL
,	NULL
M.	NULL
G.	NULL
Sarngadharan	NULL
,	NULL
S.	NULL
G.	NULL
Lindner	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1984	NULL
.	NULL

Human	NULL
T-cell	NULL
growth	NULL
factor	NULL
:	NULL
partial	NULL
amino	NULL
acid	NULL
sequence	NULL
,	NULL
cDNA	NULL
cloning	NULL
,	NULL
and	NULL
organization	NULL
and	NULL
expression	NULL
in	NULL
normal	NULL
and	NULL
leukemic	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

81:2543-2547	NULL
.	NULL

25	NULL
.	NULL

Nikaido	NULL
,	NULL
T.	NULL
,	NULL
A.	NULL
Shimizu	NULL
,	NULL
N.	NULL
Ishida	NULL
,	NULL
H.	NULL
Sabe	NULL
,	NULL
K.	NULL
Teshigawara	NULL
,	NULL
M.	NULL
Maeda	NULL
,	NULL
T.	NULL
Uchiyama	NULL
,	NULL
J.	NULL
Yodoi	NULL
,	NULL
and	NULL
T.	NULL
Honjo	NULL
.	NULL

1984	NULL
.	NULL

Molecular	NULL
cloning	NULL
of	NULL
cDNA	NULL
encoding	NULL
human	NULL
interleukin-2	NULL
receptor	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

311	NULL
:	NULL
631-635	NULL
.	NULL

26	NULL
.	NULL

Feinberg	NULL
,	NULL
A.	NULL
P.	NULL
,	NULL
and	NULL
B.	NULL
Vogelstein	NULL
.	NULL

1983	NULL
.	NULL

A	NULL
technique	NULL
for	NULL
radio-labeling	NULL
DNA	NULL
restriction	NULL
endonuclease	NULL
fragments	NULL
to	NULL
high	NULL
specific	NULL
activity	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

132:6-13	NULL
.	NULL

27	NULL
.	NULL

Maniatis	NULL
,	NULL
T.	NULL
,	NULL
E.	NULL
P.	NULL
Fritsch	NULL
,	NULL
and	NULL
J.	NULL
Sambrook	NULL
.	NULL

1982	NULL
.	NULL

Molecular	NULL
Cloning	NULL
:	NULL
a	NULL
Laboratory	NULL
Manual	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
.	NULL

109-112	NULL
.	NULL

28	NULL
.	NULL

Clemens	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

1984	NULL
.	NULL

Purification	NULL
of	NULL
eukariotic	NULL
mRNA	NULL
.	NULL

/n	NULL
Transcription	NULL
and	NULL
Translation	NULL
.	NULL

B.	NULL
D.	NULL
Hames	NULL
and	NULL
S.	NULL
J.	NULL
Higgins	NULL
,	NULL
editors	NULL
.	NULL

IRL	NULL
Press	NULL
,	NULL
Washington	NULL
.	NULL

211-220	NULL
.	NULL

29	NULL
.	NULL

Uchiyama	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Hori	NULL
,	NULL
M.	NULL
Tsudo	NULL
,	NULL
Y.	NULL
Wano	NULL
,	NULL
H.	NULL
Umadome	NULL
,	NULL
S.	NULL
Tamori	NULL
,	NULL
J.	NULL
Yodoi	NULL
,	NULL
M.	NULL
Maeda	NULL
,	NULL
H.	NULL
Sawami	NULL
,	NULL
and	NULL
H.	NULL
Uchino	NULL
.	NULL

1985	NULL
.	NULL

Interleukin-2	NULL
receptor	NULL
(	NULL
Tac	NULL
antigen	NULL
)	NULL
expressed	NULL
on	NULL
adult	NULL
T	NULL
cell	NULL
leukemia	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

76:446-453	NULL
.	NULL

30	NULL
.	NULL

Waldmann	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
structure	NULL
,	NULL
function	NULL
,	NULL
and	NULL
expression	NULL
of	NULL
interleukin-2	NULL
receptors	NULL
on	NULL
normal	NULL
and	NULL
malignant	NULL
lymphocytes	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

232:727-732	NULL
.	NULL

31	NULL
.	NULL

Proscal	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
W.	NULL
H.	NULL
Okamura	NULL
,	NULL
and	NULL
A.	NULL
W.	NULL
Norman	NULL
.	NULL

1976	NULL
.	NULL

Vitamin	NULL
D	NULL
,	NULL
its	NULL
metabolites	NULL
and	NULL
analogs	NULL
:	NULL
a	NULL
review	NULL
of	NULL
the	NULL
structural	NULL
requirements	NULL
for	NULL
biological	NULL
activity	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Nutr	NULL
.	NULL

29:1271-1282	NULL
.	NULL

32	NULL
.	NULL

Koren	NULL
,	NULL
R.	NULL
,	NULL
A.	NULL
Ravid	NULL
,	NULL
U	NULL
.	NULL

A.	NULL
Liberman	NULL
,	NULL
Z.	NULL
Hochberg	NULL
,	NULL
Y.	NULL
Weisman	NULL
,	NULL
and	NULL
A.	NULL
Novogrodsky	NULL
.	NULL

1985	NULL
.	NULL

Defective	NULL
binding	NULL
and	NULL
function	NULL
of	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
receptors	NULL
in	NULL
peripheral	NULL
mononuclear	NULL
cells	NULL
of	NULL
patients	NULL
with	NULL
end-organ	NULL
resistance	NULL
to	NULL
1,25-dihydroxyvitamin	NULL
D.	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

76:2012-2015	NULL
.	NULL

33	NULL
.	NULL

Arya	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1984	NULL
.	NULL

T-cell	NULL
growth	NULL
factor	NULL
gene	NULL
:	NULL
lack	NULL
of	NULL
expression	NULL
in	NULL
human	NULL
T-cell	NULL
leukemia-lymphoma	NULL
virus-infected	NULL
cells	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

223:1086-1087	NULL
.	NULL

34	NULL
.	NULL

Lemire	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
J.	NULL
S.	NULL
Adams	NULL
,	NULL
R.	NULL
Sakai	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Jordan	NULL
.	NULL

1984	NULL
.	NULL

1a,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
suppresses	NULL
proliferation	NULL
and	NULL
immunglobulin	NULL
production	NULL
by	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

74:657-661	NULL
.	NULL

35	NULL
.	NULL

Ringold	NULL
,	NULL
G.	NULL
M.	NULL
1983	NULL
.	NULL

Regulation	NULL
of	NULL
mouse	NULL
mammary	NULL
tumor	NULL
virus	NULL
gene	NULL
expression	NULL
by	NULL
glucocorticoid	NULL
hormones	NULL
.	NULL

Curr	NULL
.	NULL

Top	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

106:79-103	NULL
.	NULL

36	NULL
.	NULL

Vanice	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
J.	NULL
M.	NULL
Taylor	NULL
,	NULL
and	NULL
G.	NULL
M.	NULL
Ringold	NULL
.	NULL

1984	NULL
.	NULL

Gluco-corticoid-mediated	NULL
induction	NULL
of	NULL
alpha	NULL
l-acid	NULL
glycoprotein	NULL
:	NULL
evidence	NULL
for	NULL
hormone-regulated	NULL
processing	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

81:4241-4245	NULL
.	NULL

1705	NULL

